Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2025)
Historic Return on Capital Employed for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 0.14%.
- Janux Therapeutics' Return on Capital Employed fell 200.0% to 0.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.14% for FY2024, which is 600.0% up from last year.
- Per Janux Therapeutics' latest filing, its Return on Capital Employed stood at 0.14% for Q3 2025, which was down 200.0% from 0.14% recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Return on Capital Employed registered a high of 0.06% during Q3 2021, and its lowest value of 0.23% during Q2 2023.
- For the 5-year period, Janux Therapeutics' Return on Capital Employed averaged around 0.15%, with its median value being 0.14% (2025).
- Per our database at Business Quant, Janux Therapeutics' Return on Capital Employed crashed by -1200bps in 2022 and then surged by 1400bps in 2024.
- Janux Therapeutics' Return on Capital Employed (Quarter) stood at 0.09% in 2021, then crashed by -115bps to 0.19% in 2022, then decreased by -4bps to 0.2% in 2023, then skyrocketed by 42bps to 0.11% in 2024, then decreased by -26bps to 0.14% in 2025.
- Its last three reported values are 0.14% in Q3 2025, 0.14% for Q2 2025, and 0.11% during Q1 2025.